Sunday, January 01, 2006

Merck/Pfizer - Zocor RIP, but is Lipitor wounded?

TEVA announced today that the FDA has granted tentative approval for the Company's ANDA for Simvastatin Tablets USP, 5 mg, 10 mg, 20 mg, 40 mg and 80 mg.

Upon final approval, TEVA's Simvastatin Tablets will be the AB-rated generic equivalent of Merck's Zocor cholesterol lowering blockbuster.

Insiders' view: RIP Zocor. The big question is how much Lipitor business will be stolen by generic simvastatin as well? Especially since we now have Pfizers' own IDEAL study results. LOL.

IDEAL

Less than IDEAL

1 comment:

Anonymous said...

I make that Lipitor's market share will erode away with the introduction of generic simvastatin.